Press Releases - WDM Group PR Network  

TiGenix Appoints Jean Stephenne Chairman & Russell Greig Member of Board of Directors

For more information: Eduardo Bravo Chief Executive Officer eduardo.bravo@tigenix.com Claudia D'Augusta Chief Financial Officer claudia.daugusta@tigenix.com Hans Herklots Director Investor & Media Relations hans.herklots@tigenix.com +32 16 39 60 97

Tonix Pharmaceuticals Highlights Therapeutic Programs on CEONEWS.Tv

Contacts:
Tonix Pharmaceuticals Holding Corp.
Benjamin Selzer
Chief Operating Officer
(212) 980-9155 x106
Email Contact

LHA
Anne Marie Fields
(212) 838-3777
Email Contact
or
Bruce Voss
(310) 691-7100
Email Contact

Agile Therapeutics to Present at CBI's Forum on Phase II-III Clinical Study Optimization

Contact
Chantal Beaudry/Karen Famighetti for Agile Therapeutics
212-867-1762
cbeaudry@lazarpartners.com
kfamighetti@lazarpartners.com

Horizon Pharma Prices $75 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Email Contact

Media
Geoff Curtis
DJE Science
312-550-8138
Email Contact

Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
Email Contact

Ablynx and Its Partner Advance Nanobody Candidate ALX-0751 in Pre-Clinical Development

For more information, please contact Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: Email Contact Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: Email Contact Follow us on Twitter @AblynxABLX M:Communications: Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t: +44 207 920 2330 e: Email Contact

Acura Pharmaceuticals Announces Paragraph IV ANDA Filing for OXECTA(R)

Contact:
Acura Pharmaceuticals, Inc.
for Acura Investor Relations
Email Contact
847-705-7709

for Acura Media Relations
Email Contact
847-705-7709

MorphoSys's MOR103 Antibody Demonstrates Excellent Safety and Efficacy in Rheumatoid Arthritis Patients

For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Loser Head of Corporate Communications & IR Tel: +49 (0) 89 / 899 27-122 Mario Brkulj Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-454 Jessica Kulpi Specialist Corporate Communications & IR Tel: +49 (0) 89 / 899 27-332 Email Contact

Einstein-Montefiore Scientists Awarded NCI Grants to Study "Provocative Questions" in Cancer Research

For More Information, Contact:
Warren C. Lau
President & CEO
MetaStat, Inc.
(973) 744-7618

New Classroom Program Takes Aim at Bullying Prevention

Media Contact:
Courtney Manders
Stacey Bender
Bender Hammerling Group
(973) 744-0707
Courtney.Manders@bhgpr.com
Stacey.Bender@bhgpr.com

New Research Released at salesforce.com's Dreamforce 2012 Shows Companies Responding Faster to Leads

Contact:
A. Cory Maloy
Snapp Conner PR
801-319-7900
Email Contact

| ... 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | 209 | 210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | 241 | ...


Featured Articles + MORE Featured Articles >>